GlaxoSmithKline PLC found using ticker (GSK) have now 2 analysts in total covering the stock. The consensus rating is ‘Buy’. The range between the high target price and low target price is between 51.5 and 45.64 and has a mean target at 48.57. With the stocks previous close at 40.77 this is indicating there is a potential upside of 19.1%. There is a 50 day moving average of 43.53 and the 200 day MA is 41.42. The company has a market cap of $105,998m. Find out more information at: https://www.gsk.com
The potential market cap would be $126,277m based on the market concensus.
GlaxoSmithKline plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, HIV, immuno-inflammation, oncology, anti-viral, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterial, and dermatology. It also provides consumer healthcare products in wellness, oral health, nutrition, and skin health categories. The company offers its consumer healthcare products in the form of nasal sprays, tablets, syrups, lozenges, gum and trans-dermal patches, caplets, infant syrup drops, liquid filled suspension, wipes, gels, effervescents, toothpastes, toothbrushes, mouthwashes, denture adhesives and cleansers, topical creams and non-medicated patches, lip balm, gummies, and soft chews. It has collaboration agreements with 23andMe; Lyell Immunopharma; Novartis; Sanofi SA; Surface Oncology; Progentec Diagnostics; Alector; and CureVac AG., as well as strategic partnership with IDEAYA Biosciences and Vir Biotechnology GlaxoSmithKline plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.
